Portolan Capital Management LLC Has $34.50 Million Stock Holdings in Castle Biosciences, Inc. $CSTL

Portolan Capital Management LLC raised its stake in Castle Biosciences, Inc. (NASDAQ:CSTL) by 1.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,515,111 shares of the company’s stock after acquiring an additional 25,539 shares during the quarter. Castle Biosciences comprises 1.9% of Portolan Capital Management LLC’s holdings, making the stock its 15th largest position. Portolan Capital Management LLC owned 0.05% of Castle Biosciences worth $34,499,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC boosted its holdings in shares of Castle Biosciences by 139,100.0% during the third quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after acquiring an additional 1,391 shares during the period. State of Alaska Department of Revenue bought a new position in shares of Castle Biosciences during the third quarter worth approximately $35,000. CWM LLC increased its stake in shares of Castle Biosciences by 80.6% during the third quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after purchasing an additional 853 shares during the period. Jones Financial Companies Lllp lifted its holdings in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Castle Biosciences by 63.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock worth $57,000 after purchasing an additional 976 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $25.56 on Friday. The firm has a market cap of $759.90 million, a PE ratio of -30.07 and a beta of 1.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.26 and a quick ratio of 5.11. The stock’s fifty day moving average price is $34.64 and its two-hundred day moving average price is $31.61. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.15. The firm had revenue of $81.88 million during the quarter, compared to the consensus estimate of $81.19 million. Castle Biosciences had a negative return on equity of 0.89% and a negative net margin of 7.02%. As a group, research analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Analyst Ratings Changes

CSTL has been the topic of a number of research reports. KeyCorp reaffirmed an “overweight” rating and issued a $50.00 price objective on shares of Castle Biosciences in a report on Thursday, January 29th. BTIG Research lifted their target price on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Robert W. Baird boosted their target price on shares of Castle Biosciences from $41.00 to $44.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Guggenheim upped their price target on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Lake Street Capital raised their price target on shares of Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.

Insider Buying and Selling

In related news, CFO Frank Stokes sold 7,000 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $27.44, for a total transaction of $192,080.00. Following the completion of the sale, the chief financial officer owned 52,483 shares of the company’s stock, valued at $1,440,133.52. This represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Derek J. Maetzold sold 4,017 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the sale, the insider owned 87,715 shares in the company, valued at $3,509,477.15. The trade was a 4.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,682 shares of company stock worth $1,685,038 in the last ninety days. 6.50% of the stock is owned by company insiders.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.